Edwards Lifesciences delivered a strong finish to 2025, with Q4 sales growing 11.6% year-over-year to $1.57 billion and full-year sales growth reaching 10.7%. TAVR sales increased 10.6% to $1.16 billion, driven by robust clinical data (Partner 3/Partner 2) and a shift toward urgent patient management, while the TMTT segment surged over 40% to $156 million. Although adjusted EPS of $0.58 missed expectations due to elevated SG&A spending and a higher tax rate, management expressed increased confidence in its 2026 guidance of 8-10% sales growth and EPS of $2.90-$3.05. Strategic catalysts for 2026 include the U.S. launch of SAPIEN M3, upcoming PASCAL iterations, and potential CMS tailwinds, reinforcing the company's dominance in structural heart.
| Metric | Value | Change |
|---|---|---|
| Q4 Total Sales | $1.57 billion | +11.6% |
| Q4 TAVR Sales | $1.16 billion | +10.6% |
| Q4 TMTT Sales | $156 million | >+40% |
| Q4 Surgical Sales | $254 million | +2.0% |
| Q4 Adj. EPS | $0.58 | Missed expectations |
| Full Year Sales Growth | N/A | +10.7% |
| Q4 Adj. Gross Margin | 78.3% | -70 bps YoY |
| Q4 Adj. Operating Margin | 23.7% | Aligned with guidance |
Management is aggressively leveraging long-term clinical durability data—specifically the 7-year Partner 3 and 10-year Partner 2 results—to fundamentally change the treatment paradigm for aortic stenosis. By shifting the focus from 'watchful waiting' to 'intentional and urgent treatment,' Edwards is driving procedural volume growth and securing its position as the standard of care. This strategy is supported by updated European guidelines recommending TAVR for patients aged 70+ and a renewed focus on SAPIEN, creating a multi-layered growth engine.
The TMTT (Transcatheter Mitral and Tricuspid Therapies) segment is rapidly scaling, exceeding $500 million in full-year sales and growing over 40% in Q4. Strategic product launches are accelerating, with the recent FDA approval of SAPIEN M3 (mitral replacement) complementing the existing EVOQUE and PASCAL platforms. Management anticipates significant growth catalysts in Q4 2026 with the introduction of next-gen PASCAL and PASCAL for Tricuspid patients, positioning the company to achieve its $2 billion revenue target for TMTT by 2030.
Edwards is making substantial upfront investments in commercial infrastructure and patient education, evidenced by a $112 million year-over-year increase in Q4 SG&A spending. Key initiatives include a multi-year partnership with the American Heart Association to improve diagnosis and targeted educational programs in Europe aligned with new guidelines. While this spending pressured near-term EPS, management views it as a critical investment to drive future patient volume and market share gains.
The company is strictly adhering to its structural heart focus, evidenced by the decision not to close the GennaValve acquisition and the reallocation of those funds. Capital allocation priorities remain clear: investing in internal capacity expansion for high-growth areas like TAVR and TMTT, pursuing smaller tuck-in M&A opportunities, and returning capital to shareholders via share repurchases. With approximately $2 billion remaining in authorization and a strong balance sheet ($3B cash), Edwards has the flexibility to execute its strategy.
Q4 Adjusted EPS of $0.58 missed expectations, attributed to a significant step-up in SG&A spending (up $112M YoY) and a higher-than-expected tax rate (29% reported). While management frames this as strategic investment in patient access, the magnitude of the spending increase and the margin compression (Adjusted Op Margin 23.7% vs prior year) raise concerns about cost control and the sustainability of profitability if these investment levels persist.
The Surgical product group experienced a notable slowdown in Q4, growing only 2% compared to the prior year, impacted by end-of-year distributor inventory adjustments in China. While management describes this as a 'one-time event,' it highlights potential volatility in supply chains and international markets, contrasting with the robust growth seen in the core structural heart divisions.
Significant uncertainty surrounds the Moderate AS (Aortic Stenosis) opportunity. Management explicitly excluded Moderate AS from their list of 2026 catalysts and stated they 'don't know what the study result will be' regarding the PROGRESS trial. With data not expected until TCT in late 2026, this represents a key binary event that could either unlock a massive patient population or result in a costly clinical failure.
The potential CMS tailwind regarding the TAVR National Coverage Determination (NCD) remains a distant prospect. Management clarified that the final determination is not expected until Q4 2026, implying any financial benefit will likely be realized in 2027. This delay removes a near-term catalyst and leaves the U.S. market dependent on current coverage guidelines and organic adoption growth for the immediate future.
Overall: Management displayed a highly confident and assured demeanor throughout the call, emphasizing the strength of their clinical evidence and market position. CEO Bernard Zovighian was particularly bullish on the 'intentional and urgent' treatment paradigm shift, while CFO Scott Ullem maintained financial discipline despite the quarterly EPS miss, framing the spending increase as a strategic investment. The tone in Q&A remained consistent, with executives providing detailed, data-backed answers that reinforced their guidance.
Confidence: HIGH - Management repeatedly used phrases like 'increased confidence,' 'strong momentum,' and 'durable growth engine.' They provided specific clinical data points to support their optimism and maintained full-year guidance despite a slight earnings miss, indicating strong conviction in their business trajectory.
8% to 10% (constant currency)
$2.90 to $3.05
$1.55 billion to $1.63 billion
6% to 8%
$740 million to $780 million
~150 basis points
Hedging & Uncertainty: Management generally used direct and confident language regarding past performance ('proven durability,' 'strong quarter') but employed more temporal and probabilistic hedging when discussing future regulatory outcomes. Phrases like 'potential tailwind,' 'if you think about impact for 2026, negligible,' and 'we don't know what the study result will be' regarding Moderate AS indicate a cautious approach to forecasting binary events. However, they mitigated this uncertainty by using strong commitment language for financial guidance ('increased confidence,' 'we expect'), suggesting they have internal visibility that buffers external variables.
We have increased confidence in meeting our 2026 full-year sales growth rate guidance of 8% to 10%... - Scott Ullem, CFO
This is a big shift... from watchful waiting to intentional and urgent treatment of severe aortic stenosis. - Daniel Lippis, Global Leader TAVR
We intentionally upped the spending in the fourth quarter. - Scott Ullem, CFO
We don't know what the study result will be. So we are waiting... to talk more about it. - Bernard Zovighian, CEO
The conversation has completely shifted because the evidence says that you know, the benefit of doing that is not there's no upside to that. - Daniel Lippis, Global Leader TAVR
Analyst Sentiment: Analysts were largely positive, congratulating management on the strong revenue growth and market share gains. Questions focused heavily on the sustainability of TAVR growth, the specific drivers behind the recent U.S. strength, and the granularity of the increased SG&A spending.
Management Responses: Management responses were detailed and data-driven, particularly from Daniel Lippis regarding clinical trends. They were transparent about the 'unknowns' of the Moderate AS trial and the specific timeline for the CMS NCD process, while firmly defending the increased spending as necessary for long-term patient access.
Analysis of TAVR market share gains and pricing stability amidst competitor exits.
Detailed breakdown of the $112M increase in SG&A spending and its expected ROI.
The impact of European guideline changes and the 'Early TAVR' study on referral patterns.
Timeline and potential scenarios for the CMS TAVR National Coverage Determination.
Commercial progress of the SAPIEN M3 launch in the U.S. and Europe.
Visibility into the Moderate AS (PROGRESS) trial results and potential market impact.
Edwards Lifesciences is executing at a high level, leveraging best-in-class clinical data to drive a paradigm shift in the treatment of structural heart disease. The 11.6% revenue growth demonstrates the power of their strategy, and the heavy investment in commercial infrastructure positions them to capture the demand generated by new guidelines. While the Q4 EPS miss and spending spike are short-term concerns, the long-term outlook remains robust with a clear path to 8-10% growth driven by TAVR durability and the rapid scaling of TMTT. The company's focused portfolio and strong balance sheet support a positive investment thesis.
CMS has formally opened the process to reconsider the TAVR National Coverage Determination (NCD), with a final decision expected in Q4 2026. Management believes this could lead to 'coverage to label' and improved patient access.
Updated European guidelines now recommend TAVR for patients aged 70 and older (down from 75) and advocate for proactive disease management over 'watchful waiting,' significantly expanding the addressable market.
Foreign exchange rates are expected to provide an approximate $40 million tailwind to full-year 2026 sales compared to the prior year.